Cargando…

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab

PURPOSE: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated. METHODS: Commercially available ready-to-use aflibercept and brolucizumab g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schargus, Marc, Kopp, Katharina Tatjana, Helbig, Constanze, Frings, Andreas, Winter, Gerhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Association for Research in Vision and Ophthalmology 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375009/ https://www.ncbi.nlm.nih.gov/pubmed/34406342 http://dx.doi.org/10.1167/tvst.10.9.21

Ejemplares similares

Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
por: Eissing, Thomas, et al.
Publicado: (2021)

Issues with Intravitreal Administration of Anti-VEGF Drugs
por: Schargus, Marc, et al.
Publicado: (2020)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe
por: Guest, John-Michael, et al.
Publicado: (2022)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Wang, Jia-Kang, et al.
Publicado: (2018)

Incidence of severe rise in intraocular pressure after intravitreous injection of aflibercept with prefilled syringes
por: Dingerkus, Vita Louisa Sophie, et al.
Publicado: (2022)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
por: Mehta, Neesurg, et al.
Publicado: (2023)

Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment
por: Mukai, Ryo, et al.
Publicado: (2022)

Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
por: Kato, Nobuhiro, et al.
Publicado: (2023)

Brolucizumab—another anti-VEGF or beyond
por: Sharma, Ashish, et al.
Publicado: (2020)

Deformation of Aflibercept and Ranibizumab Syringes Causes Variation in Intravitreal Injection Volume and Risks Retinal Tear Formation
por: Raevis, Joseph J., et al.
Publicado: (2022)

The Effectiveness of Brolucizumab and Aflibercept in Patients with Neovascular Age-Related Macular Degeneration
por: Musiał-Kopiejka, Magdalena, et al.
Publicado: (2022)

CHANGES IN SYSTEMIC LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER INTRAVITREAL INJECTION OF AFLIBERCEPT OR BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: Angermann, Reinhard, et al.
Publicado: (2022)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
por: Kikushima, Wataru, et al.
Publicado: (2023)

The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation
por: Shigemoto, Yumi, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose
por: Veritti, Daniele, et al.
Publicado: (2023)

Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks
por: Chakraborty, Somnath, et al.
Publicado: (2022)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
por: Singh, Sumit Randhir, et al.
Publicado: (2019)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Risk of transient vision loss after intravitreal aflibercept using vial-prepared vs. the novel prefilled syringe formulation
por: Klaas, Julian E., et al.
Publicado: (2023)

Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties
por: Sivertsen, Magne Sand, et al.
Publicado: (2018)

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture
por: Malik, Deepika, et al.
Publicado: (2014)

Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
por: Wang, Jia-Kang, et al.
Publicado: (2016)

Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration
por: Haug, Sara J., et al.
Publicado: (2020)

Retinal pigment epithelial tear following intravitreal injection of brolucizumab
por: Ashkenazy, Noy, et al.
Publicado: (2021)

Marked Choroidal Thinning Observed after Intravitreal Brolucizumab Injection
por: Ueta, Yoshiki, et al.
Publicado: (2023)

Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy
por: Fukuda, Yoshiko, et al.
Publicado: (2021)

Long-term effects of intravitreal bevacizumab and aflibercept on intraocular pressure in wet age-related macular degeneration
por: Kähkönen, Mikael, et al.
Publicado: (2021)

Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK
por: Ogura, Yuichiro, et al.
Publicado: (2022)

Advanced Coats’ disease treated with intravitreal brolucizumab combined with laser photocoagulation
por: Patel, Nimesh A., et al.
Publicado: (2020)

Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema
por: Chakraborty, Somnath, et al.
Publicado: (2022)

Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report
por: Sim, Ha Eun, et al.
Publicado: (2022)

Response of extra-large pigment epithelial detachment to intravitreal brolucizumab injection
por: Chakraborty, Somnath, et al.
Publicado: (2023)

Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
por: Jung, Byung Ju, et al.
Publicado: (2019)

Role of intravitreal brolucizumab with intravitreal rtPA and pneumatic displacement for submacular hemorrhage: A case series
por: Chakraborty, Debdulal, et al.
Publicado: (2022)

Prefilled syringes for intravitreal drug delivery
por: Sassalos, Thérèse M, et al.
Publicado: (2019)

Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone II
por: Eftekhari Milani, Amir, et al.
Publicado: (2022)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis
por: Yu, Justin S, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ues7d241rr23ri79nb8tbuai2u